Phase I Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49
Phase of Trial: Phase I
Latest Information Update: 13 Mar 2015
Price : $35 *
At a glance
- Drugs VAX 161 (Primary)
- Indications Influenza A virus infections
- Focus Adverse reactions
- Sponsors VaxInnate
- 10 Apr 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 23 May 2013 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 14 Aug 2012 New trial record